Living

US FDA declines to approve Lantheus' tumor imaging kit

By Reuters Reuters
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo ANDREW KELLY Reuters

The U.S. Food and Drug Administration declined to approve Lantheus Holdings' diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related conditions at a third-party facility, the company said on Friday.

(Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 26, 2026 at 4:12 PM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER